Genedata Screener with New SPR, DMPK, HT-Flow and HT-Electrophysiology Support Showcases at SLAS2016
The software platform supports advanced screening instrumentation; extracts rich biological information from modern screening assays; harmonizes data analytics; and enables easy data access across entire research organizations
January 20, 2016
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that at SLAS2016 it will showcase how Genedata Screener® 13 supports the latest screening technologies and applications. Genedata Screener extracts data from Surface Plasmon Resonance and Thermal Shift experiments, High-throughput Flow Cytometry, Automated Patch Clamp, and High Content Screening Assays and generates high-quality information on compound pharmacology. The software makes a variety of modern technologies applicable for a wide range of scientists and enables them to systematically share their data and results across research organizations. In addition to standard screening and hit-to-lead workflows, Screener supports Combination Profiling, Target Validation, DMPK, and Compound Combination Screening. These capabilities will be detailed in a series of SLAS2016 presentations and tutorials as well as at the Genedata SLAS Booth #642 (San Diego Convention Center January 23–27).
Used by More than 50% of World’s Top 25 Pharmas
With a successful 15-year track record of providing industrial-level screening data analysis, today Genedata Screener is used by the majority of leading global pharmaceutical companies, as well as many CROs and academic research institutions. “We believe that Genedata Screener is the gold standard for screening data analysis,” said Dr. Steve Rees, Vice President of Screening Sciences and Sample Management at AstraZeneca.
The Genedata Screener platform is continuously evolving to support the latest generation of complex technologies and applications. This evolution is rooted in deep customer collaborations that drive innovative developments, which are regularly made available to the scientific community in new software releases.
Showcasing at SLAS2016
Genedata Screener 13 will be shown at SLAS2016 featuring:
- High-throughput Flow Cytometry (HT-Flow) for analysis of complete campaigns in a single session with interactive QC on cell- and well-level data.
- Biophysical Screening using a range of technologies such as Impedance, Surface Plasmon Resonance (SPR), and Thermal Shift Analysis (TSA).
- High-throughput Electrophysiology - Automated Patch Clamp (APC) experiments that integrate raw data, analysis, and storage/reporting into one optimized workflow.
- Drug Metabolism and Pharmacokinetics (DMPK) for increased analysis efficiency and result comparability for MS-based in-vitro clearance, lipophilicity, and solubility assays.
- Easy integration for complex instrumentation with the Genedata Ready-to-Run program, which is pioneering out-of-the-box integration with selected instrument platforms. Increasingly, instrument vendors are joining Read-to-Run to ensure their customers have a smooth instrument integration workflow.
Built for Collaboration
The trend towards collaborative research models is on the rise with pharmaceutical companies outsourcing projects to CROs and partnering with each other and academic screening centers. Genedata Screener provides the common platform for such collaborations as it provides standard semantics for data analysis. It also enables data and result transparency among colleagues, but more importantly, it provides a full understanding of data and results including all relevant quality indicators. Such insights are requisite for fact-based decision making as result sharing is meaningless without ensuring result integrity and traceability back to the instrument level.
“We believe Genedata Screener has become the industry-leading data analysis platform because it consistently adapts to support new screening technologies and enables close collaborations and result sharing within the scientific community,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata Screener is emblematic of the entire Genedata solution portfolio, which continuously pushes the envelope in support of the latest technologies as well as advancing the pace of automated data analysis.”
Genedata Screener next-generation screening capabilities will be detailed in the following SLAS2016 sessions. If you are unable to attend these sessions, session presentations can be made available to you by emailing email@example.com.
Podium Presentation: A Flexible Workflow for Exploration and Prototyping of Analytical Solutions in High-Content Screening
January 25 at 3:30pm–4:00pm
Track: Automation & High Throughput Technologies
Session: High Content and High Throughput Automation
Tutorial 1: High-Throughput Flow Cytometry Data Analysis with Genedata Screener
January 25 at 2:00 pm–2:45pm
Tutorial 2: SPR Data Analysis with Genedata Screener
January 26 at 9:30am–10:15am
SLAS SIG: Compound Combination
January 27 at 8:00am–9:15am
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.